The role of subcutaneous infusion 12 of apomorphine in Parkinson's disease, Expert Rev. Neurother, vol.14, pp.833-843, 2014. ,
, , p.15
Apomorphine 16 subcutaneous infusion in patients with Parkinson's disease with persistent motor 17 fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled 18 trial, Lancet Neurol, issue.18, pp.30239-30243, 2018. ,
The efficacy of apomorphine20 A non-motor perspective, Parkinsonism Relat. Disord, vol.33, pp.28-49, 2016. ,
, , p.24
Expert Consensus Group report on the use of apomorphine in the 27 treatment of Parkinson's disease-Clinical practice recommendations, Parkinsonism 28 Relat. Disord, vol.21, pp.1023-1030, 2015. ,
, , p.30
Apomorphine: A potential modifier of amyloid deposition in 31 ,
, Parkinson's disease?, Mov. Disord, vol.31, pp.668-675, 2016.
, , p.33
, Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous 34 continuous infusion of apomorphine in Parkinson's disease, Mov. Disord, vol.19, pp.35-1463, 2004.
A 5-year 37 prospective assessment of advanced Parkinson disease patients treated with 38 subcutaneous apomorphine infusion or deep brain stimulation, J. Neurol, vol.258, pp.39-579, 2010. ,
Apomorphine pump in advanced Parkinson's disease: Effects on 42 motor and nonmotor symptoms with brain metabolism correlations, J. Neurol. Sci, vol.372, pp.279-287, 2017. ,
Clinical and neuropsychological follow 2 up at 12 months in patients with complicated Parkinson's disease treated with 3 subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic 4 nucleus, J. Neurol. Neurosurg. Psychiatry, vol.77, 2006. ,
, , p.7
, Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation 8 contraindications, Parkinsonism Relat. Disord, vol.18, pp.40-44, 2012.
Continuous 12 apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced 13 ,
, Parkinson's disease: a follow-up of two years, Arch. Gerontol. Geriatr. Suppl, pp.14-291, 2004.
Continuous subcutaneous infusion of apomorphine 16 can be used safely in patients with Parkinson's disease and pre-existing visual 17 hallucinations, Parkinsonism Relat. Disord, vol.16, pp.71-72, 2010. ,
, Continuous subcutaneous apomorphine, p.20
, Parkinson's disease patients with cognitive dysfunction: A retrospective long-term 21 follow-up study, Parkinsonism Relat. Disord, 2017.
, , p.24
Cognitive disorders in Parkinson's disease: 25 Confirmation of a spectrum of severity, Parkinsonism Relat. Disord, p.28, 2015. ,
, , p.29
Quality of life in Parkinson's disease improved by apomorphine pump: the 30 OPTIPUMP cohort study, J. Neurol, pp.1-9, 2016. ,
, , p.32
, , p.33
, , p.35
EuroInf: AMulticenter Comparative 36 Observational Study of Apomorphine and Levodopa Infusion in Parkinson's Disease, p.37 ,
, Mov. Disord, vol.30, pp.510-516, 2015.
, , p.39
Chronic 40 subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease 41 compared to conventional therapy: a real life study of non motor effect, J. Park. Dis, vol.1, pp.197-203, 2011. ,
, , p.45
Diagnostic criteria for mild 46 cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force 47 guidelines, Mov. Disord, vol.27, pp.349-356, 2012. ,
The utility of the Mattis Dementia Rating Scale in 50 ,
, Parkinson's disease mild cognitive impairment, Parkinsonism Relat. Disord, vol.20, pp.1-627, 2014.
, , p.3
, J. Chacón, vol.5
, J. Kulisevsky, vol.7
, J. Olivares, vol.9
, , p.10
, , p.11
, , p.12
, Zamarbide, vol.13
Efficacy of long-term continuous subcutaneous apomorphine infusion in 14 advanced Parkinson's disease with motor fluctuations: A multicenter study ,
, , vol.23, pp.1130-1136, 2008.
, , p.17
Continuous subcutaneous apomorphine infusion does not impair the 18 dynamics of cognitive action control in mild to moderate Parkinson's disease, J. Neurol, vol.19, pp.1-7, 2017. ,
Stigma as a key 21 determinant of health-related quality of life in Parkinson's disease, Qual, Life Res, vol.25, pp.3037-3045, 2016. ,